How should I treat a urinary tract infection caused by a pan‑resistant multidrug‑resistant organism, confirmed by symptoms, pyuria and a quantitative urine culture?

Management of Pan-Resistant Multidrug-Resistant Organism (MDRO) Urinary Tract Infection

When faced with a truly pan-resistant MDRO causing symptomatic UTI with pyuria and positive quantitative culture, consult infectious disease specialists immediately and consider cefiderocol 2 g IV every 8 hours as the most promising salvage agent, while simultaneously pursuing source control measures and evaluating for clinical trial enrollment or compassionate-use programs for investigational agents. 1, 2

Immediate Assessment and Diagnostic Steps

• Verify true pan-resistance by requesting repeat susceptibility testing with extended panels including newer agents (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, ceftolozane-tazobactam, cefiderocol, plazomicin, colistin, tigecycline, fosfomycin IV, and aztreonam) before concluding all options are exhausted. 2, 3

• Obtain urine culture before any antimicrobial changes to enable targeted therapy and confirm the organism's identity, as complicated UTIs involve a broader microbial spectrum and higher resistance rates. 4

• Assess for urological complications including obstruction, incomplete bladder emptying, stones, or indwelling catheter presence, because antimicrobial therapy alone is insufficient without source control. 4

• Evaluate infection severity by checking for fever, hemodynamic instability, flank pain, or signs of sepsis, as these determine whether parenteral therapy and hospitalization are mandatory. 5, 4

Source Control Measures (Critical First Step)

• Remove or replace indwelling urinary catheters that have been in place for ≥2 weeks at the onset of treatment, as this hastens symptom resolution and reduces recurrence risk even with resistant organisms. 4

• Address underlying urological abnormalities through urgent intervention (e.g., relieving obstruction, removing stones, draining abscesses) because antimicrobial therapy will fail without correcting these structural problems. 4

• Remove urinary catheters as soon as clinically feasible to minimize ongoing infection risk and reduce the bacterial burden. 4

Antimicrobial Options for Pan-Resistant Organisms

First-Line Salvage Agent

• Cefiderocol 2 g IV every 8 hours is FDA-approved for complicated UTI including pyelonephritis and represents the most promising option for pan-resistant Gram-negative organisms, as it maintains activity against carbapenem-resistant Enterobacterales (CRE), multidrug-resistant Pseudomonas, and many extensively drug-resistant pathogens. 1, 2, 3

Alternative Parenteral Options (When Cefiderocol Unavailable or Resistant)

• Colistin (polymyxin E) at weight-based dosing (loading dose 5 mg/kg, then 2.5 mg/kg IV every 12 hours) may be considered for CRE-related UTI, though nephrotoxicity risk is substantial and efficacy data are limited. 2, 3, 6

• Fosfomycin IV (not the oral formulation) at 6-8 g IV every 8 hours can achieve high urinary concentrations against some pan-resistant organisms, though IV formulation availability is limited in many countries and should be used with caution in patients with hypernatremia, cardiac insufficiency, or renal insufficiency. 5, 7, 2, 3

• Tigecycline should not be used for UTI with bacteremia due to low serum levels and large volume of distribution, but may be considered for isolated cystitis at 100 mg IV loading dose followed by 50 mg IV every 12 hours. 5

• Aminoglycosides (plazomicin 15 mg/kg IV every 12 hours, amikacin 15 mg/kg IV once daily, or gentamicin 5 mg/kg IV once daily) should be avoided in patients with advanced CKD but may provide synergy when combined with other agents for complicated UTI. 4, 2, 3

Combination Therapy Strategies

• Aztreonam plus ceftazidime-avibactam may provide synergistic activity against metallo-beta-lactamase (MBL)-producing CRE when both agents show intermediate susceptibility individually. 2, 3

• Aztreonam plus amoxicillin-clavulanate represents another combination option for MBL-producing organisms. 2

• Double carbapenem therapy (e.g., meropenem plus ertapenem) has been used in case reports for CRE infections, though evidence is extremely limited. 2

Special Considerations for Specific Resistant Organisms

Carbapenem-Resistant Enterobacterales (CRE)

• Ceftazidime-avibactam 2.5 g IV every 8 hours is preferred for KPC-producing CRE causing complicated UTI. 4, 2, 3

• Meropenem-vaborbactam 4 g IV every 8 hours serves as an alternative for KPC-producing CRE. 4, 2, 3

• Imipenem-cilastatin-relebactam 1.25 g IV every 6 hours is another option for CRE-associated UTI. 4, 2, 3

• Plazomicin 15 mg/kg IV every 12 hours is specifically recommended for complicated UTI caused by CRE, though this represents a weak recommendation with very low quality evidence. 4

Multidrug-Resistant Pseudomonas aeruginosa

• Ceftolozane-tazobactam 1.5 g IV every 8 hours provides excellent activity against difficult-to-treat Pseudomonas. 4, 2, 3

• Ceftazidime-avibactam 2.5 g IV every 8 hours is effective for MDR Pseudomonas when ceftolozane-tazobactam is unavailable. 4, 2, 3

• Cefiderocol 2 g IV every 8 hours maintains activity against extensively drug-resistant Pseudomonas strains. 1, 2

Vancomycin-Resistant Enterococcus (VRE)

• High-dose ampicillin (18-30 g IV daily) or amoxicillin (500 mg PO/IV every 8 hours) may overcome high ampicillin MIC in urinary tract infections due to ampicillin-resistant VRE, achieving clinical and microbiological eradication rates of 88.1% and 86% respectively. 5

• Fosfomycin (oral 3 g single dose for uncomplicated UTI or IV formulation for complicated cases) has in vitro activity against VRE. 5, 7

• Nitrofurantoin retains good in vitro activity against VRE causing lower UTI. 5

• Daptomycin at 8-10 mg/kg IV daily is preferred for serious VRE infections including those with bacteremia. 5

Treatment Duration and Monitoring

• Treat for 7-14 days total, with 7 days appropriate for prompt clinical response and 14 days for delayed response or when prostatitis cannot be excluded in males. 4

• Reassess at 72 hours if there is no clinical improvement with defervescence; lack of progress warrants imaging to exclude obstruction or abscess and consideration of alternative antimicrobial strategies. 4

• Obtain follow-up urine culture after completion of therapy to confirm eradication in complicated cases. 4

• Monitor closely for drug-related toxicity including nephrotoxicity (colistin, aminoglycosides), neurotoxicity (cefepime in CKD), and electrolyte disturbances (fosfomycin). 4, 7

Critical Pitfalls to Avoid

• Do not treat asymptomatic bacteriuria in catheterized patients with pan-resistant organisms, as this leads to inappropriate antimicrobial use and further resistance without clinical benefit. 4

• Do not use oral agents (nitrofurantoin, fosfomycin oral, trimethoprim-sulfamethoxazole) for complicated UTI or when upper-tract involvement is suspected, as these achieve insufficient tissue concentrations. 4, 7

• Do not delay infectious disease consultation when facing pan-resistant organisms, as specialized expertise is essential for optimizing therapy and accessing novel agents. 5

• Do not omit source control measures such as catheter removal or obstruction relief, as antimicrobial therapy alone will fail regardless of agent selection. 4

• Do not use moxifloxacin for UTI treatment due to uncertainty regarding effective urinary concentrations. 4

When All Standard Options Are Exhausted

• Consult infectious disease specialists immediately for guidance on compassionate-use programs, clinical trial enrollment, or off-label use of investigational agents. 5

• Consider suppressive therapy with the least toxic agent showing any in vitro activity if curative treatment is impossible and symptoms are controlled. 5

• Evaluate for phage therapy or other experimental approaches through academic medical centers with research programs in antimicrobial resistance. 5

• Implement strict infection control measures to prevent patient-to-patient spread of pan-resistant organisms, which is of paramount importance when few treatment options remain. 6